Cerus: Up on FDA nod for additional use of blood purification device

Cerus

30/11/2020 15:44

** Shares of biomedical products company  CERS.O  rise 7.6%
to $4.35
    ** Co says U.S. FDA has granted approval for use of its
device for cryoprecipitation, a process of producing frozen
blood product prepared from blood plasma  urn:newsml:reuters.com:*:nBwcfWHGBa
    ** Plasma product produced by INTERCEPT Blood System,
remains transfusion ready at room temp for up to five days and
will be used for treatment and control of bleeding, including
massive hemorrhage - CERS
    ** Co plans to begin sale in California, Texas, Louisiana
and Wisconsin in 2021, with expansion to national distribution
in 2022 following anticipated approval of manufacturing site
biologics license applications
    ** CERS shares fell ~4% this year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))